Received Jul 14, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPA | HEP A (HAVRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | Y014446 | — |
A 34 years old female patient received a pediatric dose of Havrix; A 34 years old female patient received a pediatric dose of Havrix; This non-serious case was reported by a other health professional via call center representative and described the occurrence of underdose in a 34-year-old female patient who received HAV (Havrix pediatric) (batch number Y014446, expiry date 01-FEB-2026) for prophylaxis. On an unknown date, the patient received Havrix pediatric. On an unknown date, an unknown time after receiving Havrix pediatric, the patient experienced underdose (Verbatim: A 34 years old female patient received a pediatric dose of Havrix) and adult use of a child product (Verbatim: A 34 years old female patient received a pediatric dose of Havrix). The outcome of the underdose and adult use of a child product were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date:07-Jul-2025 A Medical Assistant called to report that they administered a pediatric dose of Havrix to a 34 years old female patient, which led to underdose and adult use of a child product. The reporter asked what were the next steps to follow and when did the patient had to receive the adult dose. The reporter consented to follow up.